A Pilot Study of 18F-rhPSMA-7.3-PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease
|
Decipher Prostate |
Prostate |
2026 |
Discovery |
View
|
Integration of Habitat Risk Score in Radiation Therapy for Prostate Cancer
|
Decipher Prostate |
Int J Radiat Oncol Biol Phys |
2026 |
Discovery |
View
|
Impact of a Precision Medicine Navigator on Genomic Test Utilization in Black Patients With Prostate Cancer
|
Decipher Prostate |
JCO Oncology Practice |
2026 |
Utility |
View
|
Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in pts with muscle-invasive bladder cancer (MIBC; HCRN GU 20-444)
|
TrueMRD for MIBC |
ASCO Genitourinary Cancers Symposium |
2026 |
Conferences |
View
|
Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST)
|
Decipher Prostate GRID |
BJU Int |
2026 |
Discovery |
View
|
A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity
|
Decipher Bladder GRID |
Eur Urol Oncol |
2026 |
Discovery |
View
|
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
|
Decipher Bladder |
Lancet Oncol |
2026 |
Validation, Discovery |
View
|
Exploring the biology of metastatic hormone-sensitive prostate cancer: on the road to precision medicine
|
Decipher Prostate |
J Clin Invest |
2026 |
Reviews |
View
|
Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer
|
Decipher Bladder |
Eur Urol |
2026 |
Validation, Discovery |
View
|
Machine learning-DeepSurv prediction model integrating mpMRI radiomics and genomic biomarkers for BCR-free survival and tumor response in prostate radiotherapy.
|
Decipher Prostate |
Journal of Radiation Research |
2026 |
Discovery |
View
|
A High Decipher Genomic Risk Score Is Associated with Major Pathological Progression in Patients Undergoing Active Surveillance for Prostate Cancer
|
Decipher Prostate |
Eur Urol Oncol |
2026 |
Validation |
View
|
A Novel Application of Decipher Testing in HoLEP Specimens for Risk Stratification of Incidentally Detected Prostate Cancer
|
Decipher Prostate |
Urology |
2026 |
Validation, Discovery |
View
|
Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes
|
Decipher Prostate GRID |
Eur Urol Open Sci |
2025 |
Discovery |
View
|
A Prospective Validation of the Decipher Genomic Classifier in Men With Early Localized Prostate Cancer: The VANDAAM Study
|
Decipher Prostate |
J Natl Compr Canc Netw |
2025 |
Validation |
View
|
Sociodemographic Factors Associated With Tissue-based Genomic Testing for Prostate Cancer
|
Decipher Prostate |
Urology |
2025 |
Utility |
View
|
New research presented at ATA 2024
|
Afirma Thyroid |
ATA |
2025 |
Collections, Conferences |
View
|
Unlocking the potential of long non-coding RNAs in bladder cancer
|
Decipher Bladder GRID |
Expert Rev Mol Diagn |
2025 |
Reviews |
View
|
Ultrasensitive ctDNA monitoring for organ preservation in patients with locally advanced rectal cancer
|
TrueMRD |
NPJ Precision Oncology |
2025 |
Validation |
View
|
Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer
|
Decipher Prostate |
Prostate Cancer Prostatic Dis |
2025 |
RWE, Utility |
View
|
Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment
|
Decipher Prostate GRID |
Nat Commun |
2025 |
Discovery |
View
|